USA: +1 833-909-2966 (Toll Free)
UK: +44 808-502-0280 (Toll Free)
“Designing Growth Strategies is in our DNA”
Last Updated: June 23, 2026 | Format: PDF | Report ID: FBI117651
Thank you for your interest in the
To receive a sample report, please provide the following details:
Looking to go beyond standard insights? Our premium consulting services are available for an additional fee is designed to help you gain a competitive edge.
Please let us know if you need a deep-dive on any of the following:
The global drug discovery services market size was valued at USD 19.76 billion in 2025 and is projected to grow from USD 21.11 billion in 2026 to USD 36.22 billion by 2034, exhibiting a CAGR of 7.0% during the forecast period.
Drug discovery services are specialized, outsourced research offerings that help biotechnology and pharmaceutical companies to identify, design, and optimize potential new drugs. The increasing prevalence of chronic conditions, rising outsourcing by pharmaceutical and biotechnology companies, and the expansion of biotechnology pipelines are driving greater adoption of these services in the market. The growing collaborations among academic institutes and CROs are further boosting the adoption of drug discovery services.
The growing focus on expanding service capabilities among companies, including Wuxi AppTec and Charles River Laboratories, is further driving demand for these services in the market.
Increasing Adoption of Digital Tools and Artificial Intelligence is a Key Market Trend
Pharmaceutical and biotechnology companies are focusing on shortening discovery timelines, improving R&D productivity, and minimizing late-stage failure risk, resulting in growing adoption of automation, artificial intelligence, and computational discovery platforms. AI/ML platforms are increasingly being used across hit discovery, target identification, lead optimization, virtual screening, ADMET prediction, drug repurposing, biomarker discovery, and clinical candidate prioritization.
Automation is also improving the discovery services model. Automated liquid handling and assay development, high-throughput screening, automated synthesis, cloud-based data solutions, and computational modeling enable service providers to process huge compound libraries, generate faster biological readouts, and incorporate multi-omics and structural biology data more efficiently.
Download Free sample to learn more about this report.
Increasing Prevalence of Chronic Disorders to Boost Market Growth
The increasing prevalence of chronic conditions, including cardiovascular disorders, cancer, and others, is resulting in the growing demand for innovative drugs and effective therapies, further augmenting the outsourcing of discovery services among pharmaceutical and biotechnology companies, including assay development, lead optimization, biomarker discovery, ADME/Tox studies, and others.
This, along with a growing demand for personalized drugs and the expansion of healthcare infrastructure, is driving the adoption of these services in the market. Therefore, the factors above, along with the growing focus of key companies on offering novel services, are anticipated to boost the adoption rate of these services, further contributing to the drug discovery services market growth.
High Cost Associated with Advanced Drug Discovery Technologies to Hinder Market Growth
Advanced drug discovery workflows rely on sophisticated platforms, including automated liquid handlers, high-throughput screening systems, AI-based computational platforms, bioinformatics infrastructure, cryo-electron microscopes, laboratory information management systems, and others.
These advanced technologies require significant upfront capital investment, trained professionals, software licenses, maintenance contracts, validation processes, and data-management infrastructure, which increases the overall cost of the drug discovery setup, making adoption challenging for small and mid-sized CROs, academic spinouts, and emerging biotechnology companies.
Expansion of Discovery Outsourcing Networks to Create Opportunities
The expansion of drug discovery outsourcing networks across emerging countries presents a major opportunity in the global market. There is a growing development of pharmaceutical and biotechnological R&D infrastructure, contract research organizations, advanced laboratory networks, and preclinical research facilities across countries, including China, India, and others. Additionally, rising healthcare expenditure, expanding drug pipelines, and expanding government initiatives to support biotechnology innovation are driving demand for outsourced discovery services in the region.
Limited Number of CROs in Emerging Countries to Hamper Market Growth
The limited presence of well-established CROs in various emerging nations is a key challenge for the market. Although emerging countries offer benefits such as a large patient population and lower operating costs, many nations are still deprived of a mature ecosystem of specialized contract research organizations with advanced capabilities in medicinal chemistry, target validation, ADME/DMPK studies, high-throughput screening, toxicology, computational biology, translational research, and more. Therefore, the limited number of technically advanced CROs in emerging markets may hamper the adoption of outsourcing services, further impacting the number of clinical trials and thereby limiting market growth.
Increasing Delivery of Compounds Led to Chemistry Services Segmental Dominance
Based on the service type, the market is classified into chemistry services and biology services. Chemistry services are sub-segmented into synthetic chemistry services, analytical chemistry services, and other services. Biology services are sub-segmented into in-vitro profiling, toxicology, and other services.
Chemistry services held the largest revenue share in 2025, owing to their increasing use across almost every stage of small-molecule drug discovery, driving rising demand for outsourcing drug-delivery services among pharmaceutical and biotechnology companies. This, along with the growing delivery of compounds by service providers, is expected to further contribute to the segment growth.
The biology services segment is expected to grow at a CAGR of 7.2% over the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Increasing Approval of Novel Drugs Led to Dominance of Lead Optimization Segment
Based on the discovery phase, the market is segmented into target identification & validation, hit identification, hit-to-lead, lead optimization, and others.
The lead optimization segment dominated the global market, accounting for 26.8% share in 2025.
The growth is driven by outsourcing lead-optimization services to meet the need for integrated chemistry and biology capabilities, resulting in increased approval of novel drugs.
The target identification & validation segment is set to flourish with a growth rate of 7.9% across the forecast period.
Growing Approval of Small Molecules Boosted Segment Expansion
Based on drug type, the market is segmented into small molecules and biologics.
The small molecules segment dominated the global market in 2025. Segment growth is driven by the rising prevalence of chronic diseases and the advantages of small molecules, leading to increased approval of small-molecule therapies.
The biologics segment is set to flourish with a growth rate of 7.2% across the forecast period.
Increasing Prevalence of Cancer Led to Oncology Segment Dominance
Based on therapeutic area, the market is segmented into oncology, neurological diseases, infectious diseases, cardiovascular diseases, and others.
The oncology segment dominated the market in 2025. The increasing prevalence of cancer, the growing adoption of outsourcing drug discovery services, and the rising number of CROs are driving segment growth. Furthermore, the segment is set to hold a 34.3% share in 2026.
Neurological diseases are projected to grow at a 7.4% CAGR during the forecast period.
Increasing Demand for Innovative Drugs Boosted Pharmaceutical & Biotechnological Companies Segment Growth
Based on end user, the market is divided into pharmaceutical & biotechnological companies, academic & research institutes, and others.
The pharmaceutical & biotechnological companies segment dominated the market in 2025. The increasing demand for innovative drugs and the growing number of pharmaceutical and biotechnological companies, among others, are key factors driving the segment’s growth in the market. Furthermore, the segment is set to hold a 77.0% share in 2026.
Academic & research institutes are projected to grow at a 6.1% CAGR during the forecast period.
Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America Drug Discovery Services Market Size, 2025 (USD Billion)
North America Drug Discovery Services Market Size, 2025 (USD Billion)
To get more information on the regional analysis of this market, Download Free sample
North America held the dominant share in 2024, at USD 7.34 billion, and also led in 2025, with USD 7.83 billion. The growing prevalence of chronic diseases, the rising adoption of outsourcing services, and the increasing adoption of digital tools and automation are contributing to market expansion in the region.
Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 7.46 billion in 2026, accounting for roughly 35.4% of global sales.
Europe is projected to grow at 6.2% over the coming years, the second-highest among all regions, and reach a valuation of USD 5.72 billion in 2026. The growing prevalence of chronic conditions is likely to support market growth.
The U.K. market in 2026 is estimated at around USD 1.06 billion, representing roughly 5.0% of global revenues.
Germany’s market is projected to reach approximately USD 1.27 billion in 2026, equivalent to around 6.0% of global sales.
Asia Pacific is estimated to reach USD 5.16 billion in 2026 and secure the position of the third-largest region in the market. The growing outsourcing of drug discovery services and increasing healthcare expenditure are likely to support market growth. In the region, India and China are both estimated to reach USD 0.97 billion and USD 1.80 billion, respectively, in 2026.
The Japan market in 2026 is estimated at around USD 0.85 billion, accounting for roughly 4.0% of global revenues. Japan is expected to grow as drug discovery service networks expand in the market.
China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 1.80 billion, representing roughly 8.5% of global sales.
The India market size in 2026 is estimated at around USD 0.97 billion, accounting for roughly 4.6% of global revenues.
The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 1.05 billion in 2026. The growing number of academic institutions and the rising demand for targeted therapies are accelerating drug discovery, driving market growth in the region. The Middle East & Africa are also anticipated to grow, driven by the increasing number of research institutes and by key service providers expanding their geographic presence in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 0.41 billion in 2026.
The South Africa market is projected to reach around USD 0.19 billion in 2026, representing roughly 0.9% of global revenues.
Increasing Number of Acquisitions among Other Companies to Support Their Dominance
A strong services portfolio, along with a robust focus on strategic initiatives globally, is one of the key factors contributing to these companies’ dominance in the market. Wuxi AppTec and Charles River Laboratories were major companies in the market in 2025. Furthermore, the growing focus of key companies on acquisitions and mergers among other players is likely to strengthen their presence, further contributing to the global drug discovery services market share.
Other key players, including Labcorp, are also growing in the market, primarily due to their increased focus on strengthening their service offerings.
The report provides a detailed global drug discovery services market analysis and focuses on key aspects such as leading companies and market segmentation, including service type, discovery phase, drug type, therapeutic area, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.
Request for Customization to gain extensive market insights.
Fortune Business Insights says that the global market size was USD 19.76 billion in 2025 and is projected to reach USD 36.22 billion by 2034.
In 2025, the North America regional market value stood at USD 7.83 billion.
Growing at a CAGR of 7.0%, the market will exhibit steady growth over the forecast period (2026-2034).
By service type, the chemistry services segment led the market.
The increasing prevalence of chronic disorders is driving the market's growth.
Wuxi AppTec and Charles River Laboratories are the major players in the global market.
North America dominated the market share in 2025.
Rising expansion of outsourcing facilities and growing outsourcing of drug development services are anticipated to boost the adoption of these services globally.
Security Code
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Related Reports
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
UK +44 808 502 0280 ( Toll Free )
(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com
Unlock Dental Market Intelligence
Access 74+ Detailed Reports Featuring Market Insights, Trends, Forecasts, & Competitive Analysis Across Sectors:
THANK YOU
Your Request Has Been Received
Looking to go beyond standard insights? Our premium consulting services are <span>available for an additional fee </span>is designed to help you gain a competitive edge.
Please let us know if you need a deep-dive on any of the following:
The global drug discovery services market size is projected to grow from $21.11 billion in 2026 to $36.22 billion by 2034, exhibiting a CAGR of 7.0%
Read More at:-
Subscribe News Letter
Trust Online
Contact Us
Connect with us
Information
Recognized By
D&B D-U-N-S®
Number: 861494523
© 2026 Fortune Business Insights . All rights reserved
to enhance your experience.
